U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
CRANBURY, N.J., May 09, 2017 -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that Pankaj Mohan, Ph.D., Chairman and Chief Executive Officer of Oncobiologics, will participate and present at the World Biosimilar Congress 2017 taking place May 23 – 24, 2017.
Event: The World Biosimilar Congress 2017
Presentation Date: May 23-24, 2017
Location: Hilton San Diego Resort and Spa, San Diego, CA
Dr. Mohan will present on “Production efficiency: Streamlining both the development and manufacturing process,” on May 23rd at 3:20 p.m. On the same day, Dr. Mohan will also participate in a panel discussion on Intellectual Property at 5:00 p.m. On May 24th at noon, he will moderate a roundtable discussion of industry executives on “Achieving required data for regulatory and commercial approvals.”
World Biosimilar Congress 2017
To learn more about the World Biosimilar Congress and to register for the conference please visit http://www.terrapinn.com/conference/biosimilar-congress-usa/index.stm
About Oncobiologics, Inc. and its BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from an in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com
CONTACTS: Oncobiologics: Lawrence A. Kenyon Chief Financial Officer [email protected] Media & Investors: Alex Fudukidis Russo Partners, LLC [email protected]
